Advertisement Interrad wins clearance for SecurAcath with subcutaneous securement system - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Interrad wins clearance for SecurAcath with subcutaneous securement system

Interrad Medical, a medical device company, has received the FDA 510(k) clearance for its SecurAcath peripherally inserted central catheter with subcutaneous securement system.

Interrad Medical has developed a completely new and innovative method for catheter securement called SecurAcath. The SecurAcath System utilizes a small anchor that deploys in the subcutaneous tissue just beneath the skin to hold an indwelling catheter securely in place.

According to the company, the SecurAcath system is designed to improve catheter securement by decreasing catheter maintenance time and related costs, reducing catheter-related infections by improving cleaning of catheter exit site and minimizing catheter motion, decreasing skin surface issues, and eliminating needle stick injuries that may occur when suturing catheters.

The company is currently developing a stand-alone SecurAcath device that can be used with virtually any indwelling catheter. The stand-alone SecurAcath is being designed to work with all peripherally inserted central catheter (PICC), CVC, dialysis and drainage catheters.

Joe Goldberger, president and CEO of Interrad Medical, said: “The first placements of the SecurAcath PICC will begin shortly followed by worldwide commercialization.”